Discover strategies for minimizing adverse events and overlapping toxicities in patients undergoing lenvatinib and pembrolizumab therapy for recurrent endometrial cancer.
Pembrolizumab Plus Chemo Could Represent a New SOC in Advanced/Recurrent Endometrial Cancer
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
Dostarlimab/Chemo Receives FDA Priority Review for Expanded Indication in Endometrial Cancer
Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
Sinno Spotlights Key Clinical Trials Driving Targeted Approaches in Gynecologic Oncology
Clinicians Turn Their Focus to pMMR Disease Following Immunotherapy’s Entrance Into dMMR Endometrial Cancer
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma